Dr Reddy’s Laboratories Q2 Results: Net profit drops 9.5% to ₹1,342 crore on acquisition cost, revenue up 16.5% YoY
The drugmaker’s total revenue from operations in the second quarter of current fiscal rose 16.5 per cent to ₹8,016 crore.
India's Dr Reddy's misses Q2 profit view on weak pricing in North America
Indian generic drugmaker Dr Reddy's Laboratories reported a second-quarter profit that missed analysts' expectations on Tuesday, weighed down by pricing pressure in a competitive North American market,
Dr Reddy's Labs Q2 Preview: Healthy double-digit revenue growth seen, but PAT may fall
For the July-September 2024 period, net profit is expected to decline by 3% year-on-year, based on the average estimate from four brokerages. Sales, however, are projected to increase by 13% year-on-year,
Dr Reddy's Q2 net profit falls 9.3 pc to Rs 1,341.5 cr; revenue up 16.5 pc
Pharma major Dr Reddy’s Laboratories (DRL) on Tuesday reported a 9.35 per cent decline in its consolidated net profit to Rs 1,341.5 crore for the second quarter ended September 2024. DRL had posted a net profit of Rs 1,
India's Dr Reddy's Q2 profit drops on acquisition cost, impairment charge
By Rishika Sadam and Kashish Tandon HYDERABAD/BENGALURU (Reuters) -Indian generic drugmaker Dr Reddy's Laboratories' second-quarter profit was hit by one-time charges related to its joint venture with Nestle India and Nicotinell acquisition,
ndtvprofit36m
Dr Reddy's Share Price Rises As Analysts Upgrade Rating, Hike Target Price
Systematix upgraded the stock rating to 'hold' and hiked target price to Rs 1,414 apiece, while Dolat Capital upgraded rating ...
Dr. Reddy's Laboratories rises Tuesday, still underperforms market
Dr. Reddy's Laboratories Ltd. 500124 shares inched up 0.36% to 1,272.55 Indian rupees Tuesday, on what proved to be an ...
Dr Reddy’s Financials Verified; Investor Confidence Boosted
Dr Reddy’s Laboratories (RDY) has released an update. Dr Reddy’s Laboratories’ recent financial review by Ernst & Young ...
ndtvprofit3h
Dr. Reddy's Q2 Results Review: Brokerages Maintain Cautious Stance As US Challenges Loom
Dr. Reddy's' US sales continued to struggle due to inventory adjustments and pricing pressures on key products, Citi said.
Dr Reddys Stocks: Dr. Reddy's Laboratories ended the previous trading day at Rs 1272.20.
Discover the Dr Reddys Stock Liveblog, your ultimate resource for real-time updates and insightful analysis on a prominent ...
Business Insider18h
Dr. Reddy’s Laboratories Reports Q2 Revenue Growth
Dr Reddy’s Laboratories (RDY) has released an update. Dr. Reddy’s Laboratories reported a 17% year-over-year increase in revenue for the second quarter, reaching ₹80,162 million, driven by ...
Benzinga.com20h
Dr. Reddy's Lab Delivers 'Another Good Quarter,' CEO Says As Revenue Jumps 17%
Global generics revenue grew 17% YoY, driven by sales volume gains and new launches. Dr. Reddy’s Laboratories Ltd RDY reported Tuesday a second-quarter 2025 net income of $160 million, down from ...
Dr. Reddy's Laboratories Limited (RDY) Q2 2025 Earnings Call Transcript
Ladies and gentlemen, good day, and welcome to the Quarter Two FY 2025 Earnings Conference Call of Dr. Reddy's Laboratories Limited. As a reminder, all participants' lines will be in the listen-only ...
Dr Reddy’s Q2 profits decline 9%, revenue grows 17%
Pharma major Dr Reddy’s Laboratories’ net profit declined 9 per cent at ₹1,341 crore in the second quarter ended ...
Lack of strong launch pipeline keep brokerages neutral over Dr Reddy's Labs
Despite reporting decent earnings for the July-September quarter, brokerages continue to maintain their neutral stance over ...